Repligen upgraded to Buy from Hold at Benchmark

Benchmark analyst Robert Wasserman upgraded Repligen to Buy from Hold with an $185 price target, citing improved quarterly financial performance as well as increased valuations for comparable bioprocessing stocks. Repligen has seen double-digit revenue growth and improved earnings over the past five quarters and the outlook for the remainder of 2026 "looks positive as well," the analyst tells investors.